AngioDynamics, Inc. (NASDAQ:ANGO) Stock Position Increased by BNP Paribas Financial Markets

BNP Paribas Financial Markets grew its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) by 110.4% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 159,391 shares of the medical instruments supplier's stock after acquiring an additional 83,622 shares during the quarter. BNP Paribas Financial Markets owned about 0.39% of AngioDynamics worth $1,240,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. First Eagle Investment Management LLC purchased a new stake in AngioDynamics in the second quarter valued at approximately $1,321,000. Systematic Financial Management LP raised its position in AngioDynamics by 8.4% in the second quarter. Systematic Financial Management LP now owns 2,109,561 shares of the medical instruments supplier's stock worth $12,763,000 after acquiring an additional 162,972 shares in the last quarter. CWM LLC lifted its holdings in shares of AngioDynamics by 981.3% during the 3rd quarter. CWM LLC now owns 9,732 shares of the medical instruments supplier's stock valued at $76,000 after buying an additional 8,832 shares during the last quarter. Royce & Associates LP increased its holdings in AngioDynamics by 10.8% in the 3rd quarter. Royce & Associates LP now owns 986,073 shares of the medical instruments supplier's stock valued at $7,672,000 after buying an additional 96,138 shares during the period. Finally, Segall Bryant & Hamill LLC boosted its stake in shares of AngioDynamics by 142.7% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 911,443 shares of the medical instruments supplier's stock valued at $7,091,000 after purchasing an additional 535,958 shares during the last quarter. 89.43% of the stock is owned by hedge funds and other institutional investors.

AngioDynamics Stock Up 3.0 %

Shares of NASDAQ:ANGO traded up $0.26 during midday trading on Tuesday, hitting $8.89. The stock had a trading volume of 906,580 shares, compared to its average volume of 532,468. The company's 50-day moving average price is $6.88 and its 200-day moving average price is $6.90. The company has a market capitalization of $361.24 million, a P/E ratio of -1.46 and a beta of 0.68. AngioDynamics, Inc. has a fifty-two week low of $5.26 and a fifty-two week high of $9.42.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last issued its earnings results on Thursday, October 3rd. The medical instruments supplier reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.04. AngioDynamics had a negative return on equity of 5.86% and a negative net margin of 83.95%. The firm had revenue of $67.50 million for the quarter, compared to analyst estimates of $67.93 million. During the same period in the previous year, the company posted ($0.12) earnings per share. The business's revenue was down 14.2% on a year-over-year basis. Research analysts expect that AngioDynamics, Inc. will post -0.41 EPS for the current fiscal year.

Analysts Set New Price Targets

ANGO has been the subject of a number of research analyst reports. Canaccord Genuity Group dropped their price target on AngioDynamics from $13.00 to $12.00 and set a "buy" rating for the company in a research report on Friday, October 4th. HC Wainwright reissued a "buy" rating and set a $14.00 price objective on shares of AngioDynamics in a report on Tuesday.

Insider Transactions at AngioDynamics

In other news, CEO James C. Clemmer acquired 20,000 shares of the stock in a transaction that occurred on Monday, October 7th. The shares were bought at an average cost of $6.03 per share, for a total transaction of $120,600.00. Following the acquisition, the chief executive officer now owns 681,582 shares in the company, valued at approximately $4,109,939.46. This represents a 3.02 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have bought a total of 22,568 shares of company stock worth $135,847 in the last ninety days. Insiders own 5.40% of the company's stock.

AngioDynamics Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.